U.S. Markets close in 1 hr 42 mins

Recro Pharma, Inc. (REPH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7800-0.1400 (-7.29%)
As of 2:18PM EDT. Market open.

Recro Pharma, Inc.

490 Lapp Road
Malvern, PA 19355
United States
484 395 2470
http://www.recrogainesville.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees185

Key Executives

NameTitlePayExercisedYear Born
Mr. Ryan D. LakeChief Financial Officer572.13kN/A1977
Mr. J. David Enloe Jr.Pres, CEO & DirectorN/AN/A1964
Mr. William HirschmanVP of Sales & MarketingN/AN/AN/A
Mr. Randall J. MackSr. VP of Devel.N/AN/A1965
Mr. Marshall Rizzo M.B.A.Sr. VP & Gen. Mang.N/AN/AN/A
Mr. Richard Sidwell Ph.D.VP & Chief Scientific OfficerN/AN/AN/A
Ms. Carla LusbyCorp. Sec.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.

Corporate Governance

Recro Pharma, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.